I. MODIFIED AGREEMENTS | |||
Company* (Country; Symbol) |
Company* (Country; Symbol) |
Change from original agreement |
Terms/Details (Date) |
Cellegy Pharmaceuticals Inc. (CLGY) |
ProStrakan Group plc (UK; LSE:PSK) |
They renegotiated deal under which ProStrakan distributes Rectogesic in Europe |
ProStrakan will assume support responsibility, and purchase product directly from the manufacturer; Cellegy gets $2M and up to $0.75M in milestone payments (11/10) |
Crucell NV (the Netherlands; CRXL) |
Ark Therapeutics Group plc (UK; LSE:AKT) |
Ark renewed its its PER.C6 technology licensing agreement |
Ark got research and commercial rights to develop and manufacture gene-based drugs using the technology; terms were not disclosed (1/18) |
Third Wave Technologies Inc. (TWTI) |
Digene Corp. (DIGE) |
Third Wave dismissed a lawsuit against Digene over patents related to human papilloma-virus |
The agreement does not include the grant of any license, nor does it include payments by either company (1/13) |
I. TERMINATED AGREEMENTS | |||
Micromet AG* (Germany) |
Enzon Pharmaceuticals Inc. (ENZN) |
They ended a deal to identify and develop antibody-based drugs for treating inflammatory and autoimmune diseases |
They had combined technology in single-chain antibodies in the April 2002 collaboration; Micromet gets rights to the lead candidate (MT203) generated in the deal, and Enzon would get royalties; cross-license and marketing agreements between the companies remained unchanged (11/28) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
LSE = London Stock Exchange. | |||
